Shareholders Approve Reverse Stock Split to Address Nasdaq Listing Requirements
CDLX sits 27% above its 52-week low of $0.57.
Summary
Cardlytics shareholders approved a reverse stock split, giving the Board discretion to execute it to help the company meet Nasdaq's minimum bid price requirement.
Key Events · Corporate Governance and Compliance · CDLX
-
Reverse Stock Split Approved
Stockholders approved a proposal allowing the Board to effect a reverse stock split at a ratio between 1-for-5 and 1-for-15, along with a proportionate reduction in authorized shares. This addresses the company's need to meet Nasdaq's minimum bid price requirement, following a DEF 14A filing on 2026-04-09 seeking this approval.
-
Directors Re-elected
Three nominees (Amit Gupta, Jack Klinck, and Shrishti Gupta) were elected to serve as Class II directors until the 2029 annual meeting.
-
Auditor Ratified
The selection of Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year 2026 was ratified by stockholders.
-
Executive Compensation Approved
Stockholders approved, on an advisory basis, the compensation of the company's named executive officers.
Analysis · CDLX · Technology
Cardlytics shareholders have approved a proposal granting the Board the option to implement a reverse stock split at a ratio between 1-for-5 and 1-for-15. This is a critical step for the company, which is currently trading below $1.00, to meet Nasdaq's minimum bid price requirement and avoid potential delisting. The approval provides the company with the necessary flexibility to maintain its exchange listing.
At the time of this filing, CDLX was trading at $0.73 on NASDAQ in the Technology sector, with a market capitalization of approximately $41.8M. The 52-week trading range was $0.57 to $3.28. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.